|
|
Technology Transfer
 |
Baylor Research Institute's (BRI) quest to bring innovative treatments from the
laboratory workbench to the patient bedside often leads to commercially relevant
inventions in the laboratory. BRI works closely with the scientists to determine when an
invention is patentable, providing legal guidance and acting as the point of contact for
companies interested in developing and commercializing the inventions.
To date, BRI has patented more than 40 inventions, while forming a biotech company, ODC Therapy, Inc.
ODC develops, produces, and distributes customized cancer vaccines, including a melanoma
vaccine, to individual patients and monitors their immune response after treatment.
ODC brings personalized therapies from early-stage clinical trials to marketing approval
and commercial distribution. The technology to produce the cancer vaccines is based on
the ongoing work at Baylor Institute for Immunology Research under the supervision of
Jacques Banchereau, Ph.D. and Karolina Palucka, M.D., Ph.D.
ODC cancer vaccines are produced by removing dendritic cell precursors from a patient,
culturing and loading these cells with the tumor antigens, and then reintroducing them
into the same patient. ODC Therapy Inc. is a privately held company owned by Baylor
Health Care System.
|
|
Baylor Intranet | 
Baylor Portal